- Choose Conventional (mg/dL, pg/mL) or SI (mmol/L, pmol/L) units to match your lab report. Switching units clears the fields.
- Enter total serum calcium, phosphorus, albumin, and intact PTH from the same blood draw.
- Select the patient's CKD stage or dialysis modality — this sets the correct PTH target band.
- Results update live: albumin-corrected calcium, the Ca×P product, and a stage-specific PTH status (low / in-target / high), each with a colored badge and a plain-language interpretation.
All computation runs in your browser; no values are stored or transmitted.
When to Use
Use this tool when interpreting a CKD-MBD (chronic kidney disease–mineral and bone disorder) laboratory panel in any patient with CKD G3a–G5 or on maintenance dialysis. It bundles the three calculations clinicians repeat at every mineral-metabolism review: the calcium–phosphorus product, albumin-corrected calcium, and stage-specific PTH target interpretation.
Appropriate population
Adults with CKD G3a–G5 (eGFR < 60 mL/min/1.73 m²) or receiving hemodialysis / peritoneal dialysis, who have a recent serum calcium, phosphorus, albumin, and intact PTH drawn together. Most useful when albumin is abnormal (so total calcium needs correction) and when deciding whether to start, hold, or titrate phosphate binders, calcimimetics, or active vitamin D.
When NOT to rely on it
Do not apply in acute kidney injury (values change too fast), in patients with normal kidney function, or as a standalone treatment trigger. A single Ca×P product or PTH value is never an indication to start or stop therapy — KDIGO emphasizes trends across serial measurements. Corrected calcium is unreliable in profound hypoalbuminemia, paraproteinemia, or acid–base disturbance; ionized calcium is preferred there.
Pearls & Pitfalls
Treat trends, not single values
KDIGO bases therapy decisions on the trajectory of serial calcium, phosphorus, and PTH measurements together — not on one isolated number. A modestly elevated PTH that is falling needs different action than the same value rising over months.
Phosphorus first
Persistently high phosphorus is the usual driver of a high Ca×P product and of secondary hyperparathyroidism. Dietary phosphate restriction (especially additives), adequate dialysis, and binders taken with meals usually do more than escalating calcimimetics or vitamin D.
Pitfalls
(1) Correcting calcium in severe hypoalbuminemia or paraproteinemia over- or under-estimates true ionized calcium — measure ionized calcium instead. (2) PTH assays are not interchangeable; always interpret against the reporting lab's own normal range, which is why this tool uses a ×ULN band rather than a fixed number. (3) Avoid driving PTH fully into the normal range in dialysis patients — over-suppression risks adynamic bone disease.
Why Use It
Hyperphosphatemia, an elevated calcium–phosphorus product, and a PTH outside the target window are each independently associated with vascular and valvular calcification, fracture, and cardiovascular mortality in CKD. Because total calcium is bound to albumin, a low albumin can mask true hypercalcemia or fabricate apparent hypocalcemia — so correcting calcium for albumin before acting is essential. This calculator standardizes those steps so binder, calcimimetic, and vitamin-D decisions rest on the corrected, stage-appropriate numbers.
CKD-MBD Lab Calculator — Ca×P Product, Corrected Calcium & PTH Staging
Enter your mineral metabolism lab results to calculate the calcium-phosphorus product, correct your calcium for albumin, and see whether your PTH is within the KDIGO 2024 target range for your dialysis status.
⚕ Corrected Ca = Total Ca + 0.8 × (4.0 − Albumin). Ca×P product uses corrected calcium. PTH targets: KDIGO 2017/2024 recommend HD/PD iPTH ≈ 2–9× the assay upper-normal limit; CKD G3–G5 not on dialysis: maintain within normal to modestly above-normal. All values require physician interpretation in clinical context.
Next Steps
Use the result to support — not replace — clinical judgment.
- Interpret the value against the targets shown in the calculator and the Evidence section below, in the context of the full clinical picture.
- Trend serial measurements rather than acting on a single result; confirm abnormal or unexpected values before changing management.
- Apply the relevant KDIGO / specialty-guideline threshold and document the indication.
- Escalate or refer to nephrology when results are out of range, rapidly changing, or discordant with the clinical picture — and discuss the implications with the patient.
Evidence & References
Formula & Equations
| Quantity | Equation |
|---|---|
| Albumin-corrected calcium (mg/dL) | Measured total Ca + 0.8 × (4.0 − serum albumin in g/dL) |
| Albumin-corrected calcium (SI, mmol/L) | Measured total Ca + 0.02 × (40 − serum albumin in g/L) |
| Calcium–phosphorus product (mg²/dL²) | Corrected calcium (mg/dL) × phosphorus (mg/dL) |
KDIGO target reference ranges
| Parameter | Target |
|---|---|
| Serum phosphorus | Lower toward the normal range (KDIGO 2017 2C); avoid hyperphosphatemia |
| Serum calcium (corrected) | Avoid hypercalcemia; keep within the normal range |
| Ca×P product (legacy KDOQI target) | < 55 mg²/dL² (< 4.4 mmol²/L²) |
| Intact PTH — dialysis (G5D) | ≈ 2–9 × the upper limit of the assay's normal range |
| Intact PTH — CKD G3a–G5 (non-dialysis) | Evaluate and treat persistent, progressive, or markedly elevated values; optimal level not defined |
The corrected-calcium ("Payne") formula assumes a normal albumin of 4.0 g/dL (40 g/L). The Ca×P product is a legacy KDOQI construct; KDIGO 2017/2024 instead emphasize treating calcium and phosphorus individually and following trends. Ionized calcium is preferred when albumin is markedly abnormal.
Evidence & References
Target ranges follow the KDIGO Clinical Practice Guideline for CKD-MBD (2017 update and 2024 revision). The albumin-correction equation is the Payne formula (1973); the calcium–phosphorus product threshold derives from KDOQI (2003). Observational data (Block et al.; Tentori et al.) link disordered mineral metabolism to mortality and calcification.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1–59.
- KDIGO. 2024 Clinical Practice Guideline for the Evaluation and Management of CKD-MBD (revision in progress / published updates). Kidney International, 2024.
- National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–S201.
- Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4(5893):643–646.
- Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218.
- Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the DOPPS. Am J Kidney Dis. 2008;52(3):519–530.
